Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

Carna Initiates Dosing in the MAD Part of Phase 1 Trial of AS-0871

Carna Announces Completion of Dosing in the BA Part of Phase 1 trial of AS-0871

Carna Announces Successful Development of New Tablet Formulation of AS-0871

Revision of Results Forecast for the Fiscal Year Ending December 31, 2022

Notice of Issuance of 20th Series of Stock Acquisition Rights (Third Party Allotment of Floating Strike Warrants)

FY2022 Q3 Presentation

Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2022

FY2022 Q2 Presentation